Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A2/B chimeras

Protein Expression and Purification

Volumn 74, Issue 1, 2010, Pages 16-23

  Tinker, Juliette K ^a   Davis, Chadwick T ^a,b   Arlian, Britni M ^a,c  

^a BOISE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c The College of Idaho   (United States)

Author keywords

A2B chimera; Cholera toxin; Expression; Mucosal adjuvant; Trafficking; Yersinia pestis

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; CHOLERA TOXIN; LCRV PROTEIN, YERSINIA; PORE FORMING CYTOTOXIC PROTEIN;

ARTICLE; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; PLAGUE; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING; YERSINIA ENTEROCOLITICA; YERSINIA INFECTION; YERSINIA PESTIS;

ANTIGENS, BACTERIAL; BACTERIAL VACCINES; BLOTTING, WESTERN; CHOLERA TOXIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; PLAGUE; PORE FORMING CYTOTOXIC PROTEINS; YERSINIA ENTEROCOLITICA; YERSINIA INFECTIONS; YERSINIA PESTIS;

ESCHERICHIA COLI; YERSINIA ENTEROCOLITICA; YERSINIA PESTIS;

EID: 77957862166     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2010.04.021     Document Type: Article

References (63)

1. M.B. Prentice, and L. Rahalison Plague Lancet 369 2007 1196 1207
2. T.V. Inglesby, D.T. Dennis, D.A. Henderson, J.G. Bartlett, M.S. Ascher, E. Eitzen, A.D. Fine, A.M. Friedlander, J. Hauer, J.F. Koerner, M. Layton, J. McDade, M.T. Osterholm, T. O'Toole, G. Parker, T.M. Perl, P.K. Russell, M. Schoch-Spana, and K. Tonat Plague as a biological weapon: medical and public health management. Working group on civilian biodefense Jama 283 2000 2281 2290
3. R.W. Titball, and E.D. Williamson Yersinia pestis (plague) vaccines Expert. Opin. Biol. Ther. 4 2004 965 973
4. R.J. Cohen, and J.L. Stockard Pneumonic plague in an untreated plague-vaccinated individual Jama 202 1967 365 366
5. K.F. Meyer, G. Smith, L. Foster, M. Brookman, and M. Sung Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs J. Infect. Dis. 129 Suppl. 1974 S85 12
6. R.W. Titball, and E.D. Williamson Vaccination against bubonic and pneumonic plague Vaccine 19 2001 4175 4184
7. C.G. Rodrigues, C.M. Carneiro, C.T. Barbosa, and R.A. Nogueira Antigen F1 from Yersinia pestis forms aqueous channels in lipid bilayer membranes Br. J. Med. Biol. Res. 25 1992 75 79
8. A. Holmstrom, J. Olsson, P. Cherepanov, E. Maier, R. Nordfelth, J. Pettersson, R. Benz, H. Wolf-Watz, and A. Forsberg LcrV is a channel size-determining component of the Yop effector translocon of Yersinia Mol. Microbiol. 39 2001 620 632
9. J. Pettersson, A. Holmstrom, J. Hill, S. Leary, E. Frithz-Lindsten, A. von Euler-Matell, E. Carlsson, R. Titball, A. Forsberg, and H. Wolf-Watz The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation Mol. Microbiol. 32 1999 961 976
10. E.D. Williamson, H.C. Flick-Smith, C. Lebutt, C.A. Rowland, S.M. Jones, E.L. Waters, R.J. Gwyther, J. Miller, P.J. Packer, and M. Irving Human immune response to a plague vaccine comprising recombinant F1 and V antigens Infect. Immun. 73 2005 3598 3608
11. J.L. Goodin, D.F. Nellis, B.S. Powell, V.V. Vyas, J.T. Enama, L.C. Wang, P.K. Clark, S.L. Giardina, J.J. Adamovicz, and D.F. Michiel Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague Protein Expr. Purif. 53 2007 63 79
12. B.S. Powell, G.P. Andrews, J.T. Enama, S. Jendrek, C. Bolt, P. Worsham, J.K. Pullen, W. Ribot, H. Hines, L. Smith, D.G. Heath, and J.J. Adamovicz Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague Biotechnol. Prog. 21 2005 1490 1510
13. D.G. Heath, G.W. Anderson Jr., J.M. Mauro, S.L. Welkos, G.P. Andrews, J. Adamovicz, and A.M. Friedlander Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine Vaccine 16 1998 1131 1137
14. S.T. Smiley Current challenges in the development of vaccines for pneumonic plague Expert. Rev. Vaccines 7 2008 209 221
15. T. Jones, J.J. Adamovicz, S.L. Cyr, C.R. Bolt, N. Bellerose, L.M. Pitt, G.H. Lowell, and D.S. Burt Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection Vaccine 24 2006 1625 1632
16. R.M. Robins-Browne Yersinia enterocolitica 1997 ASM Press Washington, DC
17. R. Rappuoli, M. Pizza, G. Douce, and G. Dougan Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins Immunol. Today 20 1999 493 500
18. J. Holmgren, C. Czerkinsky, N. Lycke, and A.M. Svennerholm Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant Am. J. Trop. Med. Hyg. 50 1994 42 54
19. N. Lycke, and J. Holmgren Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens Immunology 59 1986 301 308
20. M. Pizza, M.M. Giuliani, M.R. Fontana, E. Monaci, G. Douce, G. Dougan, K.H.G. Mills, R. Rappuoli, and G. Del Giudice, mucosal vaccines: nontoxic derivatives of LT and CT as mucosal adjuvants Vaccine 19 2001 2534 2541
21. R.J. Salmond, J.A. Luross, and N.A. Williams Immune modulation by the cholera-like enterotoxins Expert. Rev. Mol. Med. 2002 2002 1 16
22. G. Hajishengallis, S. Arce, C.M. Gockel, T.D. Connell, and M.W. Russell Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance. applications for oral infections J. Dent. Res. 84 2005 1104 1116
23. A.C. Schnitzler, J.M. Burke, and L.M. Wetzler Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells Infect. Immun. 75 2007 3150 3159
24. S. Uddowla, L.C. Freytag, and J.D. Clements Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens Vaccine 25 2007 7984 7993
25. J.E. Eyles, S.J. Elvin, A. Westwood, C.S. Lebutt, H.O. Alpar, S. Somavarapu, and E.D. Williamson Immunisation against plague by transcutaneous and intradermal application of subunit antigens Vaccine 22 2004 4365 4373
26. J. Sanchez, and J. Holmgren Cholera toxin structure, gene regulation and pathophysiological and immunological aspects Cell Mol, Life Sci, 65 2008 1347 1360
27. S.A. Plotkin, W.A. Orenstein, and P.A. Offit Vaccines fifth edition 2008 Elsevier Health New York
28. M.G. Jobling, and R.K. Holmes Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras Infect. Immun. 60 1992 4915 4924
29. M.G. Jobling, L.M. Palmer, J.L. Erbe, and R.K. Holmes Construction and characterization of versatile cloning vectors for efficient delivery of native foreign proteins to the periplasm of Escherichia coli Plasmid 38 1997 158 173
30. F. Sultan, L.L. Jin, M.G. Jobling, R.K. Holmes, and S.L. Stanley Jr. Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin Infect. Immun. 66 1998 462 468
31. X. Li, J.L. Erbe, C.V. Lockatell, D.E. Johnson, M.G. Jobling, R.K. Holmes, and H.L. Mobley Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis Infect. Immun. 72 2004 7306 7310
32. T. Harakuni, H. Sugawa, A. Komesu, M. Tadano, and T. Arakawa Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems Infect. Immun. 73 2005 5654 5665
33. C.M. Gockel, and M.W. Russell Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein Immunology 116 2005 477 486
34. G. Hajishengallis, S.K. Hollingshead, T. Koga, and M.W. Russell Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits J. Immunol. 154 1995 4322 4332
35. S.O. Hatic 2nd, J.A. McCann, and W.D. Picking In vitro assembly of novel cholera toxin-like complexes Anal. Biochem. 292 2001 171 177
36. J. Sanchez, G. Wallerstrom, M. Fredriksson, J. Angstrom, and J. Holmgren Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination J. Biol. Chem. 277 2002 33369 33377
37. S.J. Streatfield, M. Sandkvist, T.K. Sixma, M. Bagdasarian, W.G. Hol, and T.R. Hirst Intermolecular interactions between the A and B subunits of heat-labile enterotoxin from Escherichia coli promote holotoxin assembly and stability in vivo Proc. Natl. Acad. Sci. USA 89 1992 12140 12144
38. S.J. Hardy, J. Holmgren, S. Johansson, J. Sanchez, and T.R. Hirst Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro Proc. Natl. Acad. Sci. USA 85 1988 7109 7113
39. L.M. Guzman, D. Belin, M.J. Carson, and J. Beckwith Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter J. Bacteriol. 177 1995 4121 4130
40. J. Sanchez, J. Holmgren, and A.M. Svennerholm Recombinant fusion protein for simple detection of Escherichia coli heat-stable enterotoxin by GM1 enzyme-linked immunosorbent assay J. Clin. Microbiol. 28 1990 2175 2177
41. C. Rodighiero, A.T. Aman, M.J. Kenny, J. Moss, W.I. Lencer, and T.R. Hirst Structural basis for the differential toxicity of cholera toxin and Escherichia coli heat-labile enterotoxin. Construction of hybrid toxins identifies the A2-domain as the determinant of differential toxicity J. Biol. Chem. 274 1999 3962 3969
42. J.K. Tinker, J.L. Erbe, and R.K. Holmes Characterization of fluorescent chimeras of cholera toxin and Escherichia coli heat-labile enterotoxins produced by use of the twin arginine translocation system Infect. Immun. 73 2005 3627 3635
43. J. Hill, S.E. Leary, K.F. Griffin, E.D. Williamson, and R.W. Titball Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization Infect. Immun. 65 1997 4476 4482
44. J.K. Pullen, G.W. Anderson Jr., S.L. Welkos, and A.M. Friedlander Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes Infect. Immun. 66 1998 521 527
45. L.E. Quenee, B.J. Berube, J. Segal, D. Elli, N.A. Ciletti, D. Anderson, and O. Schneewind Amino acid residues 196-225 of LcrV represent a plague protective epitope Vaccine 28 2010 1870 1876
46. K.A. Overheim, R.W. Depaolo, K.L. Debord, E.M. Morrin, D.M. Anderson, N.M. Green, R.R. Brubaker, B. Jabri, and O. Schneewind LcrV plague vaccine with altered immunomodulatory properties Infect. Immun. 73 2005 5152 5159
47. C.G. Branger, J.D. Fetherston, R.D. Perry, and R. Curtiss 3rd Oral vaccination with different antigens from Yersinia pestis KIM delivered by live attenuated Salmonella typhimurium elicits a protective immune response against plague Adv. Exp. Med. Biol. 603 2007 387 399
48. C.G. Branger, A. Torres-Escobar, W. Sun, R. Perry, J. Fetherston, K.L. Roland, and R. Curtiss 3rd Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica Vaccine 27 2009 5363 5370
49. A.P. Anisimov, S.V. Dentovskaya, E.A. Panfertsev, T.E. Svetoch, P.K. Kopylov, B.W. Segelke, A. Zemla, M.V. Telepnev, and V.L. Motin Amino acid and structural variability of Yersinia pestis LcrV protein Infect. Genet. Evol. 10 2009 137 145
50. A. Roggenkamp, A.M. Geiger, L. Leitritz, A. Kessler, and J. Heesemann Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen Infect. Immun. 65 1997 446 451
51. P.I. Bastiaens, I.V. Majoul, P.J. Verveer, H.D. Soling, and T.M. Jovin Imaging the intracellular trafficking and state of the AB5 quaternary structure of cholera toxin Embo J. 15 1996 4246 4253
52. I.V. Majoul, P.I. Bastiaens, and H.D. Soling Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells J. Cell Biol. 133 1996 777 789
53. L.E. Quenee, and O. Schneewind Plague vaccines and the molecular basis of immunity against Yersinia pestis Hum. Vaccine 5 2009
54. M. Sandkvist, L.O. Michel, L.P. Hough, V.M. Morales, M. Bagdasarian, M. Koomey, V.J. DiRita, and M. Bagdasarian General secretion pathway (eps) genes required for toxin secretion and outer membrane biogenesis in Vibrio cholerae J. Bacteriol. 179 1997 6994 7003
55. M. Tauschek, R.J. Gorrell, R.A. Strugnell, and R.M. Robins-Browne Identification of a protein secretory pathway for the secretion of heat-labile enterotoxin by an enterotoxigenic strain of Escherichia coli Proc. Natl. Acad. Sci. USA 99 2002 7066 7071
56. L. De Haan, A.R. Hearn, A.J. Rivett, and T.R. Hirst Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway Infect. Immun. 70 2002 3249 3258
57. E.C. Lavelle, A. Jarnicki, E. McNeela, M.E. Armstrong, S.C. Higgins, O. Leavy, and K.H. Mills Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent J. Leukoc. Biol. 75 2004 756 763
58. K. Eriksson, M. Fredriksson, I. Nordstrom, and J. Holmgren Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development Infect. Immun. 71 2003 1740 1747
59. E. Cox, F. Verdonck, D. Vanrompay, and B. Goddeeris Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa Vet. Res. 37 2006 511 539
60. J. Holmgren, and C. Czerkinsky Mucosal immunity and vaccines Nat. Med. 11 2005 S45 53
61. J. Holmgren, C. Czerkinsky, K. Eriksson, and A. Mharandi Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges Vaccine 21 Suppl. 2 2003 S89 95
62. N.R. Thomson, S. Howard, B.W. Wren, M.T. Holden, L. Crossman, G.L. Challis, C. Churcher, K. Mungall, K. Brooks, T. Chillingworth, T. Feltwell, Z. Abdellah, H. Hauser, K. Jagels, M. Maddison, S. Moule, M. Sanders, S. Whitehead, M.A. Quail, G. Dougan, J. Parkhill, and M.B. Prentice The complete genome sequence and comparative genome analysis of the high pathogenicity Yersinia enterocolitica strain 8081 PLoS Genet. 2 2006 e206
63. P. Hu, J. Elliott, P. McCready, E. Skowronski, J. Garnes, A. Kobayashi, R.R. Brubaker, and E. Garcia Structural organization of virulence-associated plasmids of Yersinia pestis J. Bacteriol. 180 1998 5192 5202